Healthcare is one of the most reliably essential sectors in the economy — people do not defer medical care during recessions the way they defer vacations or kitchen renovations. This structural demand makes healthcare a natural hunting ground for dividend investors. But not all healthcare dividend stocks are created equal, and the contrast between UnitedHealth Group (UNH) and CVS Health (CVS) illustrates the most important distinction in income investing: the difference between a dividend compounder and a high-yield value trap.
Two Very Different Healthcare Businesses
UnitedHealth Group operates through two primary segments. UnitedHealthcare is the largest health insurer in the United States, covering approximately 50 million members. Optum is a healthcare services and technology platform — including pharmacy benefit management, healthcare IT, and a growing network of physician practices and surgery centers. Optum is the faster-growing segment and increasingly the more important one: it generates roughly half of UnitedHealth's operating earnings despite being the lesser-known business.
What makes UnitedHealth exceptional as a business is its vertical integration. The company simultaneously sells insurance, manages pharmacy benefits, employs physicians, and operates the data analytics infrastructure that ties it all together. This creates switching costs, cross-selling opportunities, and operating leverage that most healthcare companies cannot replicate.
CVS Health is a different kind of complexity. It began as a pharmacy chain, acquired pharmacy benefit manager Caremark in 2007, and then made its most consequential bet: the $69 billion acquisition of health insurer Aetna in 2018. The thesis was that integrating pharmacy, PBM, and insurance would create a vertically integrated healthcare company capable of competing with UnitedHealth. The execution has been more difficult than anticipated.
CVS today operates across three segments: pharmacy and consumer health (the retail stores), health services (PBM and specialty pharmacy), and health care benefits (Aetna). The integration is ongoing, the debt load from the Aetna acquisition remains significant, and the retail pharmacy business faces structural headwinds from reimbursement pressure and competition from Amazon Pharmacy and Mark Cuban's Cost Plus Drugs.
Dividend History: Growth vs. Stability
UnitedHealth has increased its dividend for more than 14 consecutive years with a 10-year compound growth rate approaching 15–20%. The dividend began at minimal levels and has grown dramatically as the business scaled. The payout ratio has remained below 30% throughout — an unusually low figure that reflects both the capital-intensive nature of managed care (insurers must hold regulatory reserves) and management's conservative approach to capital allocation.
CVS has a longer and more complicated dividend history. The company has maintained its dividend without a cut for more than a decade, but growth has been uneven. Following the Aetna acquisition, CVS froze its dividend from 2018 to 2022 to focus on debt reduction — a rational decision that nonetheless violated the expectation of annual increases that dividend investors depend on. Dividend growth has resumed, but at modest rates constrained by the need to continue deleveraging.
This matters enormously for how you frame each stock. UnitedHealth's dividend history reflects a business that has grown into its capital return program. CVS's dividend history reflects a business managing the aftermath of a transformative, leverage-intensive acquisition.
The Yield Question
CVS typically yields 3–4%, sometimes higher during periods of market stress. UnitedHealth yields approximately 1.5% under most conditions. The yield gap is significant and tempting — CVS pays roughly double the income per dollar invested.
But yield alone is a dangerous metric. The question is not what the yield is today; it is what the dividend will be in 10 years, and whether it will get there without cuts. A 1.5% yield growing at 15% annually becomes a 6% yield on cost after 10 years. A 4% yield growing at 3–4% annually — constrained by debt service — becomes roughly 5.5% yield on cost after the same period. The compounder wins on a long enough horizon, with less risk of a cut along the way.
Applying the Weiss Method
UnitedHealth is an instructive Weiss case study. Because it has grown so rapidly, its historical yield range has compressed over time — the 2015 yield profile is not comparable to the 2025 profile. The more relevant Weiss window is the past five years, during which meaningful yield spikes have occurred during periods of political risk (Medicare for All debates), regulatory pressure on Medicare Advantage rates, and the broader 2022 healthcare selloff. Those moments of elevated yield have consistently been good entry points.
CVS presents a different Weiss challenge: a high and variable yield that reflects genuine uncertainty, not simply cyclical cheapness. When a stock's yield is elevated because the market is uncertain about whether the dividend is sustainable, the Weiss signal can be misleading. The method works best on stocks with stable, growing dividends where price fluctuations drive yield changes. For CVS, earnings uncertainty and balance sheet risk also drive yield changes — a fundamentally different situation.
Quality Score Analysis
Payout ratio: UnitedHealth's sub-30% payout is a model of sustainability. CVS's ratio is higher and more variable, with the debt service obligation adding an implicit constraint on dividend growth that payout ratio alone does not capture.
Dividend streak: UnitedHealth's 14+ years of uninterrupted growth is clean and unambiguous. CVS's multi-year freeze from 2018 to 2022 breaks the streak in economic terms, even if no formal cut occurred.
Dividend CAGR: UnitedHealth at 15–20% over 10 years is among the highest of any large-cap dividend payer. CVS at low single digits since the freeze reflects the post-acquisition constraints.
FCF quality: Both generate substantial free cash flow, but UnitedHealth's is cleaner and more predictable. CVS's free cash flow is partly allocated to debt reduction, which directly competes with dividend growth.
The Honest Verdict
UnitedHealth is one of the highest-conviction dividend compounders in the S&P 500. The business has structural advantages that are unlikely to erode — managed care scale, Optum's vertical integration, and the essential nature of health insurance. The low current yield is the price of quality. For a 15–20 year income portfolio, it belongs in the core.
CVS is not a bad company, but it is a complicated one at a pivotal moment. The Aetna integration thesis could prove correct, and if CVS successfully deleverages and resumes consistent dividend growth, the current yield will look attractive in retrospect. But "could prove correct" is not the same as "will prove correct." CVS requires a higher risk tolerance and close monitoring of the debt reduction progress and insurance segment margins.
If you hold only one, hold UnitedHealth and wait for moments when the Weiss signal turns undervalued. If you hold both, size CVS smaller and treat it as a speculative value position rather than a core income holding.
The most dangerous thing an income investor can do is reach for yield without understanding why it is elevated. CVS's yield is elevated for real reasons. UnitedHealth's yield is low for equally real reasons.
Current signals and quality scores: UNH analysis · CVS analysis